Israel's prominence in cannabis research and medicine draws regular investor interest in its listed companies. This guide lays out the landscape factually — who is public, how you can access them, and the risks specific to the sector. It is not a recommendation to buy or sell anything.
Important: This guide is informational only and is not investment advice. We are not financial advisers. Cannabis equities are high-risk and volatile; do your own research and consult a licensed professional before making any decision.
The listed pure-plays
A small number of Israeli cannabis companies are accessible to public-market investors, primarily through U.S. listings:
- InterCure / Canndoc (Nasdaq: INCR; TASE: INCR). Israel's largest licensed producer and the sector's clearest profitability story, reporting roughly NIS 270 million in 2025 revenue with positive operating cash flow (GlobeNewswire). See our InterCure profile.
- IM Cannabis (Nasdaq: IMCC). A smaller operator reporting C$54.7 million in 2025 revenue, now selling its European business to cut debt and refocus on Israel (IM Cannabis IR). See our IM Cannabis profile.
Other names in the ecosystem — BOL Pharma, Panaxia and others — trade on the Tel Aviv Stock Exchange or are privately held, and access varies. Some companies in the sector have faced severe financial distress, including insolvency.
How investors access them
The most direct route for international investors is the U.S.-listed shares (INCR and IMCC on Nasdaq), which also means these companies file with the SEC — a useful source of audited, standardised financial information. The Tel Aviv Stock Exchange lists additional names but is less accessible to many foreign retail investors.
Sector-specific risks
Several risks are particular to Israeli cannabis equities and worth understanding before forming any view:
- Regulatory whiplash. The market is shaped by unresolved policy fights — the import-tariff dispute and the proposed smokable-cannabis phase-out — either of which could materially change company economics. See our Regulation hub.
- Import-cost exposure. Because Israel imports much of its flower, trade policy and currency moves feed directly into margins.
- Thin profitability. Much of the global cannabis sector is loss-making; revenue growth has often not translated into profit, and balance sheets can be fragile.
- Small-cap volatility. These are small companies; share prices can move sharply on single regulatory or corporate events.
- Governance and related-party risk. As IM Cannabis's CEO-linked European sale illustrates, related-party transactions occur in this sector and warrant careful reading of the terms.
The balanced view
The bull case rests on Israel's research credibility, pharmaceutical standards, and a large, established domestic patient base; the bear case rests on import dependence, price competition, thin margins and regulatory uncertainty. Both are real, and reasonable observers weigh them differently. Nothing here resolves that for you — it is a starting point for your own research, not a verdict.
For the underlying businesses, see the Companies hub and our profiles of InterCure and IM Cannabis; for the trade backdrop, Israel's cannabis export industry.
Compiled and reviewed by Tamar Levin, Editor. Sources are linked inline. This guide is informational and is not medical or legal advice; consult a licensed physician about your own treatment.
More on this topic: Companies.